Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Editorials
You have accessRestricted Access

Wound Healing in the Kidney: Complex Interactions in Renal Interstitial Fibrogenesis

Raimund Hirschberg
JASN January 2005, 16 (1) 9-11; DOI: https://doi.org/10.1681/ASN.2004110901
Raimund Hirschberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

The degree of renal interstitial fibrosis, i.e., the poorly organized accumulation of extracellular matrix (ECM) proteins such as collagens (types I, III, and IV), fibronectin, laminins, and others, has emerged as the pathohistologic entity that correlates better with the degree of renal filtration failure than any other histologic descriptor and better predicts the rate of progression to end-stage renal failure in chronic renal diseases (1,2). Although injured tubular cells moderately contribute to ECM production, the primary matrix-generating cells in the renal interstitium seem to be myofibroblasts. Normal kidneys are devoid of myofibroblasts, and only a few of their precursor cells, fibroblasts, can be found in interstitial spaces. Effective fibrogenesis requires multiplication of fibroblasts and their transformation into the matrix-producing myofibroblast phenotype. Since the pivotal experiments in Border’s laboratory, TGF-β has emerged as a master regulator of fibrogenesis in the renal interstitium and in other parenchymal organs (3,4). However, other cells and intercellular mediators play important roles. As in many processes in nature, the baseline state of tissue maintenance is regulated by a balance of promoting factors and antagonists, and departure from this baseline requires a relative increase in permissive activity and loss of inhibitory factors. Increasing fibrosis-propagating cytokines include TGF-β and PDGF. Bone morphogenetic protein 7 (BMP7) and hepatocyte growth factor have emerged recently as inhibitors of fibrosis.

Renal fibrogenesis may resemble processes that occur during wound healing of the skin. In this latter condition, a cut through the skin is followed by degranulation of platelets, which provides to the wound a cocktail of growth factor-cytokines (EGF, IGF-I, TGF-β, and PDGF) that orchestrate repair. Immigrating neutrophils secrete IL-1 and TNF-α, and macrophages provide TGF-β, heparin-binding–EGF, fibroblast growth factor, TNF-α, and other factors to the wound. Fibroblast proliferation is regulated by TGF-β and PDGF, and myofibroblast transition is especially regulated by TGF-β in collaboration with IGF, ED-A+ splice variant of fibronectin, and other factors (5).

In this simplified model of wound healing, macrophages play key roles. Heavy and prolonged inflammatory infiltrates lead to more severe scarring (5,6). Of note, even large fetal skin wounds heal without scars, and fetal wound healing occurs with far fewer or even without inflammatory infiltrates, highlighting the role of macrophages and other inflammatory cells in fibrogenesis.

The importance of the macrophage infiltrate has also been appreciated in renal fibrogenesis. These cells are thought to be attracted into the renal interstitium by peritubular chemokine gradients that are formed by basolateral secretion of compounds such as the c-c-chemokines monocyte chemoattractant protein-1 (MCP-1) and RANTES as NF-κB–mediated responses to tubular cell injury. MCP-1 may also activate macrophages, which in response increases their expression of TGF-β and perhaps other cytokines (7). Through these peptides, macrophages are thought to act on tubular cells, fibroblasts, and themselves by autocrine and paracrine modes of actions. TNF-α and IL-1α target tubular cells, raising MCP-1 secretion, which may attract and activate more macrophages in a vicious cycle that maintains and worsens the infiltrate (8). TGF-β and PDGF cause fibroblast proliferation, and the former contributes to myofibroblast transition of injured tubular cells, a mechanism for the recruitment of myofibroblasts by epithelial-mesenchymal transformation (9), and to the expression of ECM proteins. Thus, interactions between macrophages and residential cells are thought to involve primarily humoral mechanisms.

In recent experimental studies, Zhang et al. examined the contribution of direct interactions between immigrating macrophages and tubular cells (10). These investigators generated in vitro experimental evidence in support of a model of competition between two avenues of direct cell–cell interactions between tubular cells and macrophages, one resulting in profibrogenic activation of tubular cells and another geared toward preventing this profibrogenic cell–cell contract (11,12). In this model, engagement of leukocyte function antigen-1 (LFA-1) on the surface of macrophages with tubular cell intercellular adhesion molecule-1 (ICAM-1) leads to TGF-β–mediated activation of a fibrogenic program in tubular cells, whereas binding of macrophage CD44 to tubular cell membrane hyaluronic acid extensions (“cables”) prevents this physical association via ICAM-1 and, hence, profibrogenic tubular cell activation (10–12). Moreover, these authors described that the hyaluronic acid cables on tubular cell surfaces are regulated by BMP7 (13). Increased hyaluronic acid cables reduce engagement of ICAM-1 by macrophages perhaps by geographically preventing close contacts between macrophages and the basolateral membrane of tubular cells. Although these findings will require in vivo confirmation, they elucidate a novel mechanism by which macrophage infiltrates may directly engage tubular cells and, in addition, describe a novel mechanism of antifibrogenic action of BMP7.

BMP7 has recently emerged as an antifibrogenic, endogenously expressed growth factor in kidney, which is downregulated before or early at the onset of fibrogenesis in experimental renal diseases (14,15). Exogenously administered recombinant human BMP7 (rhBMP7) reduces renal interstitial fibrosis in experimental obstructive and diabetic nephropathy (14,16,17). The studies by Zhang et al. provide insights into one mechanism of BMP7’s antifibrogenic function, namely increasing hyaluronic acid cables on tubular cell surface (10). However, there is also evidence that a broad range of effects of BMP7 in other cell types reduce TGF-β–mediated fibrosis programs (18). Recent findings suggest that BMP7-dependent, smad5-mediated, transcriptionally activated smad6 blocks the TGF-β smad2/3 signal transduction pathway by reducing the nuclear translocation of phosphorylated smad2/3 (19). Such opposing interaction between BMP7-dependent smad (smad1 and smad5) and the TGF-β–induced smad signals (smad2 and smad3) has also been elucidated as a mechanism by which BMP7 blocks TGF-β–induced epithelial-mesenchymal transformation (20). In vitro, BMP7 reduces the increased expression of several ECM proteins and matrix accumulation–promoting regulatory molecules that are induced by TGF-β via smad2/3 pathways (18).

Exogenous administration of rhBMP7 in rodents with obstructive nephropathy also reduces the interstitial macrophage infiltrate (14). It remains unclear whether and how the effects of BMP7 on tubular cell surface hyaluronic acid cables may contribute to reduced interstitial infiltration with macrophages. Perhaps interactions between macrophages and tubular cells via ICAM-1 increase tubular cell chemokine secretion, which would attract and activate more macrophages, but this is speculative.

The interstitial macrophage infiltrate seems to be of prominent importance for interstitial fibrogenesis as inferred by lessons from studies in wound healing. Some experts believe that the absence of fibrogenesis in fetal wound healing results from the virtual absence of an early inflammatory (macrophage) infiltrate (5,6,21). Perhaps prevention of the renal interstitial macrophage infiltrate or reduction of the paracrine or direct cell–cell interactions of inflammatory cells with residential renal cells reduces or prevents renal interstitial fibrogenesis. Indeed, in proof-of-concept in vivo gene therapy experiments, the reduction of MCP-1 activity reduces both interstitial macrophage infiltration and fibrosis (22,23). As a more practical approach, the small molecule proteasome inhibitors PS-341 (Velcade) and PS-519, which specifically prolong the half-life of the endogenous NF-κB inhibitor IκB, may emerge as a clinically useful therapy to reduce interstitial macrophage infiltration and, hence, fibrogenesis (24).

Insights into the mechanisms of renal interstitial fibrogenesis have generated novel therapeutic targets, and interventions have been tested experimentally in in vitro and in vivo studies. In addition to rhBMP7, hepatocyte growth factor reduces fibrogenesis in the kidney by inducing TGF-β–induced factor (TGIF) and SnoN, two smad3-transcriptional co-repressors that oppose TGF-β signals (25). Small molecule inhibitors of activin receptor–like kinases (Alk4, -5, and -7), which inhibit the TGF-β receptor I (Alk5) kinase but not the BMP-activated receptor kinases, block global TGF-β functions in vitro, but their in vivo efficacy on renal fibrogenesis has not yet been demonstrated (26,27). Inhibition of the TGF-β–induced fibrosis mediator connective tissue growth factor, such as with monoclonal antibodies, could be a suitable therapy. There is experimental evidence, albeit very limited, that simvastatin reduces TGF-β–dependent transcriptional activation of connective tissue growth factor in fibroblasts (28). If confirmed, then statins might gain yet another indication in patients with renal disease. TGF-β–induced renal fibroblast proliferation requires activation of abelson, and PDGF also contributes to this process. Indeed, imatinib mesylate, an inhibitor of abelson and the PDGF receptor kinase, reduces fibrogenesis in experimental obstructive nephropathy (29).

The study of mechanisms of interactions between cells in the renal interstitium in several laboratories has recently provided several new insights that may translate into novel antifibrogenic therapies for the management of patients with chronic renal disease.

  • © 2005 American Society of Nephrology

References

  1. ↵
    Mackensen-Haen S, Bader R, Grund KE, Bohle A: Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin Nephrol 15: 167–171, 1981
    OpenUrlPubMed
  2. ↵
    Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI: Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 43: 1046–1051, 1994
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Border WA, Noble NA: Targeting TGF-beta for treatment of disease. Nat Med 1: 1000–1001, 1995
    OpenUrlCrossRefPubMed
  4. ↵
    Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286–1292, 1994
    OpenUrlCrossRefPubMed
  5. ↵
    Martin P: Wound healing—Aiming for perfect skin regeneration. Science 276: 75–81, 1997
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Cowin AJ, Brosnan MP, Holmes TM, Ferguson MW: Endogenous inflammatory response to dermal wound healing in the fetal and adult mouse. Dev Dyn 212: 385–393, 1998
    OpenUrlCrossRefPubMed
  7. ↵
    Wang S, Hirschberg R: Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 278: F554–F560, 2000
    OpenUrlPubMed
  8. ↵
    Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, van Es LA: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48: 1477–1486, 1995
    OpenUrlCrossRefPubMed
  9. ↵
    Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776–1784, 2003
    OpenUrlCrossRefPubMed
  10. ↵
    Zhang XL, Selbi W, de la Motta C, Hascall V, Phillips AO: Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-β1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol 16: 80–90, 2005
    OpenUrl
  11. ↵
    Ito T, Williams JD, Fraser D, Phillips AO: Hyaluronan attenuates transforming growth factor-β1-mediated signaling in renal proximal tubular epithelial cells. Am J Pathol 164: 1979–1988, 2004
    OpenUrlCrossRefPubMed
  12. ↵
    Zhang XL, Selbi W, de la Motte C, Hascall V, Phillips A: Renal proximal tubular epithelial cell transforming growth factor-β1 generation and monocyte binding. Am J Pathol 165: 763–773, 2004
    OpenUrlCrossRefPubMed
  13. ↵
    Selbi W, de la Motte C, Hascall V, Phillips A: BMP-7 modulates hyaluronan-mediated proximal tubular cell-monocyte interaction. J Am Soc Nephrol 15: 1199–1211, 2004
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, Morrissey J: Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 279: F130–F143, 2000
    OpenUrlCrossRefPubMed
  15. ↵
    Wang S, LaPage J, Hirschberg R: Loss of tubular bone morphogenetic protein-7 (BMP7) in diabetic nephropathy. J Am Soc Nephrol 12: 2392–2399, 2001
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Davies MR, Lund RJ, Hruska KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14: 1559–1567, 2003
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H, Klahr S, Hruska KA: Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 63: 2037–2049, 2003
    OpenUrlCrossRefPubMed
  18. ↵
    Wang S, Hirschberg R: BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 284: F1006–F1013, 2003
    OpenUrlCrossRefPubMed
  19. ↵
    Wang S, Hirschberg R: Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 279: 23200–23206, 2004
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964–968, 2003
    OpenUrlCrossRefPubMed
  21. ↵
    Martin P, Parkhurst SM: Parallels between tissue repair and embryo morphogenesis. Development 131: 3021–3034, 2004
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, Suzuki S, Sato W, Morita Y, Maruyama H, Egashira K, Matsuo S: Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 14: 1496–1505, 2003
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Takase O, Hirahashi J, Takayanagi A, Chikaraishi A, Marumo T, Ozawa Y, Hayashi M, Shimizu N, Saruta T: Gene transfer of truncated IκBα prevents tubulointerstitial injury. Kidney Int 63: 501–513, 2003
    OpenUrlCrossRefPubMed
  24. ↵
    Elliott PJ, Zollner TM, Boehncke WH: Proteasome inhibition: A new anti-inflammatory strategy. J Mol Med 81: 235–245, 2003
    OpenUrlCrossRefPubMed
  25. ↵
    Liu Y: Hepatocyte growth factor in kidney fibrosis: Therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 287: F7–F16, 2004
    OpenUrlCrossRefPubMed
  26. ↵
    DaCosta Byfield S, Major C, Laping NJ, Roberts AB: SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 65: 744–752, 2004
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Laping NJ: ALK5 inhibition in renal disease. Curr Opin Pharmacol 3: 204–208, 2003
    OpenUrlCrossRefPubMed
  28. ↵
    Watts K, Spiteri M: Connective tissue growth factor expression and induction by transforming growth factor-β is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 287: L1323–L1332, 2004
    OpenUrlCrossRefPubMed
  29. ↵
    Wang S, Wilkes MC, Leof EB, Hirschberg R: Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 2005, in press
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 16 (1)
Journal of the American Society of Nephrology
Vol. 16, Issue 1
1 Jan 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Wound Healing in the Kidney: Complex Interactions in Renal Interstitial Fibrogenesis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Wound Healing in the Kidney: Complex Interactions in Renal Interstitial Fibrogenesis
Raimund Hirschberg
JASN Jan 2005, 16 (1) 9-11; DOI: 10.1681/ASN.2004110901

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Wound Healing in the Kidney: Complex Interactions in Renal Interstitial Fibrogenesis
Raimund Hirschberg
JASN Jan 2005, 16 (1) 9-11; DOI: 10.1681/ASN.2004110901
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • The Road Ahead for Research on Air Pollution and Kidney Disease
  • Missing Self and DSA—Synergy of Two NK Cell Activation Pathways in Kidney Transplantation
  • Animal Model of Pregnancy after Acute Kidney Injury Mirrors the Human Observations
Show more Editorials

Cited By...

  • Genomic Analysis of Kidney Allograft Injury Identifies Hematopoietic Cell Kinase as a Key Driver of Renal Fibrosis
  • Secretion of ERP57 is important for extracellular matrix accumulation and progression of renal fibrosis, and is an early sign of disease onset
  • Bone Marrow Ly6Chigh Monocytes Are Selectively Recruited to Injured Kidney and Differentiate into Functionally Distinct Populations
  • Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire